Rezolute, Inc., a company focused on treating hypoglycemia caused by hyperinsulinism, announced that its abstract for a Phase 3 study of its drug Ersodetug will be presented at ENDO 2025 in San ...

Alterity Therapeutics (ATHE) announced the presentation of data from Alterity’s Biomarkers of progression in Multiple System Atrophy, bioMUSE, natural history study at the 35th International Symposium ...

The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan demonstrated End-tidal Control’s association with reduced anesthetic ...